1-4 of 4
Shiro Jimi, PhD
Close
Sort by
Journal Articles

Mechanisms of Discrepancy Between CD33 Expression and Gemtuzumab Ozogamicin-Induced Cytotoxicity in Leukemia Cells.

Yasushi Takamatsu, MD, Shiro Jimi, PhD, Nanako Toyota, Shuuji Hara, PhD, Yuka Yoshimura, Junji Suzumiya, MD, Kazuo Tamura, MD
Journal: Blood
Blood (2009) 114 (22): 4812.
https://doi.org/10.1182/blood.V114.22.4812.4812
Published: 2009
Journal Articles

Ubenimex Enhances the Gemtuzumab Ozogamicin-Induced Cytotoxicity Against Myeloid Leukemia Cells.

Yasushi Takamatsu, MD, PhD, Shiro Jimi, PhD, Yuka Yoshimura, Junji Suzumiya, MD, PhD, Kazuo Tamura, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 4370.
https://doi.org/10.1182/blood.V110.11.4370.4370
Published: 2007
Journal Articles

All- Trans Retinoic Acid Accelerates Migration of MOLT3 to SDF-1 α/CXCL12 through the Phosphatidylinositol 3 Kinase (PI3K)/Akt Pathway.

Shiro Jimi, PhD, Taichi Matsumoto, Junji Suzumiya, MD, Shuji Hara, PhD, Yasushi Takamatsu, MD, Kazuo Tamura, MD
Journal: Blood
Blood (2006) 108 (11): 4221.
https://doi.org/10.1182/blood.V108.11.4221.4221
Published: 2006
Journal Articles

Am80, a RARα Specific Synthetic Retinoid Induced a Strong Growth Inhibition in Hematologic Malignant Cells Including Myeloid and Lymphoid Cell Lines.

Shiro Jimi, PhD, Kota Mashima, Mitsukuni Sakabe, Emiko Ushijima, Junji Suzumiya, MD, Shuji Hara, Ph.D, Kazuo Tamura, MD
Journal: Blood
Blood (2005) 106 (11): 4438.
https://doi.org/10.1182/blood.V106.11.4438.4438
Published: 2005